The Influence of HIV-Status Disclosure on Adherence, Immunological and Virological Outcomes among HIV-Infected Patients Started on Antiretroviral Therapy in Dar-es- Salaam, Tanzania

Show simple item record

dc.contributor.author Buma, D.
dc.contributor.author Bakari, M.
dc.contributor.author Fawzi, W.
dc.contributor.author Mugusi, F.
dc.date.accessioned 2016-09-14T07:09:50Z
dc.date.available 2016-09-14T07:09:50Z
dc.date.issued 2015-10
dc.identifier.citation Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV. Prevention of HIV-1 infection with early antiretroviral therapy. New England journal of medicine. 2011 Aug 11;365(6):493-505. en_GB
dc.identifier.issn 2380-5536
dc.identifier.uri http://hdl.handle.net/123456789/2062
dc.description.abstract Background: Disclosure of HIV status pose a great challenge in many societies due to associated stigma. We prospectively investigated whether or not HIV-status disclosure before commencement of antiretroviral therapy (ART) has influence on adherence, immunological response and viral load suppression (VLS) in HIV-infected patients. Methods: Using systematic sampling, 520 HIV-infected patients were selected prior to initiation of ART from 4 HIV care and treatment clinics (CTC) in Dar-es-Salaam. Data on HIV status disclosure and adherence were collected using a structured questionnaire, while viral load and CD4+ T-cell counts were determined through laboratory investigations. Patients were followed up for one year. We performed logistic regression to determine the association between HIV status disclosure and the outcomes. Results: Four hundred and sixty two patients were analyzed, of whom 136 (29.4%) were males. Sixty (13%) and 310 (67.1%) of the study patients disclosed their HIV-status early and late respectively, while 92 (19.9%) did not disclose their HIV-status. Between males and females in each category, male had low number of HIV-status disclosure, p<0.05. The proportion adhering to therapy of 96.7% was higher in patients who disclosed their HIV-status before ART initiation compared to that of 85.4% among those who disclosed later on, p=0.0109. There was a statistically significant difference in terms of CD4+ T-cell counts recovery between patients who disclosed earlier and those who disclosed later on, p=0.0341. A statistically significant difference in terms of viral load suppression was also noted between early and later HIV status disclosure, p=0.0036. Conclusion: Disclosure of HIV-status before initiation of ART improves patients’ adherence, and has a positive influence on CD4+ T-cell counts recovery as well as viral load suppression. en_GB
dc.language.iso en en_GB
dc.publisher SciForschen en_GB
dc.relation.ispartofseries O p e n h u b f o r s c i e n t i f i c r e s e a r c h;
dc.subject Early HIV-status disclosure en_GB
dc.subject Adherence; CD4+T-cell counts recovery en_GB
dc.subject Viral load suppression en_GB
dc.subject Tanzania en_GB
dc.title The Influence of HIV-Status Disclosure on Adherence, Immunological and Virological Outcomes among HIV-Infected Patients Started on Antiretroviral Therapy in Dar-es- Salaam, Tanzania en_GB
dc.type Article en_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MUHAS IR


Advanced Search

Browse

My Account